AstraZeneca Launches New Digital Resources for ARIMIDEX® (anastrozole) Tablets to Help Educate Patients About ARIMIDEX Direct

Resources Provide Program Enrollment Information and Encourage Patients to Share the Information With Others

<0> AstraZenecaStephanie Andrzejewski, +1 302-885-8896 </0>

AstraZeneca (NYSE: AZN) today launched new digital resources to educate patients on how to enroll in . Resources include a outlining the enrollment process for ARIMIDEX and a that can be shared via social media platforms and symbolizes support for the program.

Breast cancer treatments can impact patients financially. In fact, research has found that the estimated lifetime costs of medical care for breast cancer patients in the United States can be up to $100,000. However, there are programs like AstraZeneca’s ARIMIDEX , which can help reduce financial strain for patients taking ARIMIDEX.

ARIMIDEX is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer. Prescription ARIMIDEX is only for postmenopausal women. ARIMIDEX should not be taken if you are pregnant because it may harm your unborn child. Do not take ARIMIDEX if you are allergic to any of its ingredients. Additional Important Safety Information provided below.

ARIMIDEX enables eligible patients with a valid prescription to have delivered directly to their home for $40 per month, including shipping and handling. Patients who enroll in ARIMIDEX could save more than $4,000 per year through the program. ARIMIDEX is not valid for prescriptions purchased under Medicaid or similar assistance programs.

ARIMIDEX is a development in AstraZeneca’s long tradition of innovation in oncology. Over the years, AstraZeneca has produced treatment options in the therapeutic area of oncology, including medications for treating postmenopausal women with hormone receptor-positive early breast cancer. Further, AstraZeneca has long played a leadership role in raising awareness about breast cancer and the importance of screening. The AstraZeneca Foundation was one of the founders of National Breast Cancer Awareness Month. In addition, AstraZeneca is proud to be an award recipient of the CEO Gold Standard Accreditation from the CEO Roundtable on Cancer since 2006.

Patients or physicians with questions can call 1-800-637-3616 to contact ARIMIDEX Customer Service between 8:00 AM and 6:00 PM ET, Monday through Friday, excluding holidays.

ARIMIDEX is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer.

ARIMIDEX is approved for the initial treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. Patients with hormone receptor-negative disease and patients who did not previously respond to tamoxifen therapy rarely responded to ARIMIDEX.

For more information, see your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development, and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: .

For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit or call 1-800-AZandMe (292-6363).

1978200 10/12

Campbell J, Ramsey S. The costs of treating breast cancer in the US: A synthesis of published evidence. . 2009; 27(3): 199-209.

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.